Harvey I Cantor

USPTO Granted Patents = 20 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 169(Granted Patents)

Location History:

Belmont, MA (US) (2002 - 2007)
Boston, MA (US) (1985 - 2023)
Wellesley, MA (US) (1988 - 2023)

Company Filing History:

20 out of 1,210

Dana-farber-cancer Institute Inc.

patents

3 out of 2,893

The General Hospital Corporation

patents

where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202904 - IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells (2025-01-21),

2. 11597934 - Methods and compositions for reducing immunosuppression by tumor cells (2023-03-07),

3. 11591403 - IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells (2023-02-28),

4. 11590213 - Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis (2023-02-28),

5. 11371989 - Intracellular osteopontin regulates the lineage commitment of lymphoid subsets (2022-06-28),

6. 10876120 - Methods and compositions for reducing immunosupression by tumor cells (2020-12-29),

7. 10596195 - Discovery of regulatory T cells programmed to suppress an immune response (2020-03-24),

8. 10548957 - Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis (2020-02-04),

9. 9944931 - Methods and compositions for reducing immunosupression by tumor cells (2018-04-17),

10. 8197817 - Regulation of mink in thymocytes and T lymphocytes (2012-06-12),

11. 7160986 - BCL-xγ, a novel BCL-x isoform, and uses related thereto (2007-01-09),

12. 6472170 - BCL-XY, a novel BCL-X isoform, and uses related thereto (2002-10-29),

13. 5238839 - Nucleic Acids Encoding proteins which induce immunological effector cell (1993-08-24),

14. 5149785 - Proteins which regulate gene expression of the interleukin-2 receptor (1992-09-22),

15. 5049659 - Proteins which induce immunological effector cell activation and (1991-09-17),

Title: The Innovative Mind of Harvey I Cantor

Introduction: Harvey I Cantor, a distinguished inventor hailing from Wellesley, MA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Cantor's most recent patents focus on advancements in artificial intelligence algorithms for autonomous vehicles, revolutionizing the way we approach transportation and safety on the roads.

Career Highlights: With a career spanning over two decades, Cantor has been at the forefront of technological innovation. His work in developing cutting-edge medical devices for minimally invasive surgeries has saved countless lives and improved patient outcomes worldwide.

Collaborations: Throughout his career, Cantor has collaborated with leading research institutions and universities to further his research and bring his inventions to life. His partnerships with top engineers and scientists have led to the successful commercialization of several groundbreaking technologies.

Conclusion: Harvey I Cantor's passion for innovation and his relentless pursuit of technological advancement have solidified his reputation as a visionary inventor. His contributions to the world of technology continue to inspire future generations of inventors and shape the way we interact with the world around us.

This text is generated by artificial intelligence and may not be accurate.